Physiologically based pharmacokinetic modeling and simulation in pediatric drug development
A R Maharaj, A N Edginton, A R Maharaj, A N Edginton
Abstract
Increased regulatory demands for pediatric drug development research have fostered interest in the use of modeling and simulation among industry and academia. Physiologically based pharmacokinetic (PBPK) modeling offers a unique modality to incorporate multiple levels of information to estimate age-specific pharmacokinetics. This tutorial will serve to provide the reader with a basic understanding of the procedural steps to developing a pediatric PBPK model and facilitate a discussion of the advantages and limitations of this modeling technique.
Figures
References
- Edginton A.N., Theil F.P., Schmitt W., Willmann S. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin. Drug Metab. Toxicol. 2008;4:1143–1152.
- Jones H., Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2013;2:e63.
- Zhao P., et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 2011;89:259–267.
- Huang S.M., Abernethy D.R., Wang Y., Zhao P., Zineh I. The utility of modeling and simulation in drug development and regulatory review. J. Pharm. Sci. 2013;102:2912–2923.
- Poulin P., et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach J. Pharm. Scie-pub ahead of print 3 May 2011.
- Maharaj A.R., Barrett J.S., Edginton A.N. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013;15:455–464.
- Björkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br. J. Clin. Pharmacol. 2005;59:691–704.
- Johnson T.N., Zhou D., Bui K.H. Development of physiologically-based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents. Biopharm. Drug Dispos. 2014;35:341–352.
- Khalil F., Läer S. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug. AAPS J. 2014;16:226–239.
- Willmann S., et al. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin. Pharmacokinet. 2014;53:89–102.
- Jiang X.L., Zhao P., Barrett J.S., Lesko L.J., Schmidt S. Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. CPT Pharmacometrics Syst. Pharmacol. 2013;2:e80.
- Pan Y., Grillo J., Hsu V., Zhang L., Sinha V., Huang S. Application of the FDA PBPK knowledgebase in evaluating model predictability for drug-drug interactions. Clin.Pharmacol.Ther. 2014;95
- West G.B., Brown J.H., Enquist B.J. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science. 1999;284:1677–1679.
- Anderson B.J., Holford N.H. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 2009;24:25–36.
- Edginton A.N., Shah B., Sevestre M., Momper J.D. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years. Clin. Pharmacokinet. 2013;52:693–703.
- Edginton A.N., Willmann S. Physiology-based versus allometric scaling of clearance in children; an eliminating process based comparison. Paed. Perinat. Drug Ther. 2006;7:146–153.
- Tod M., Jullien V., Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet. 2008;47:231–243.
- Edginton A.N. Knowledge-driven approaches for the guidance of first-in-children dosing. Paediatr. Anaesth. 2011;21:206–213.
- Leong R., et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin. Pharmacol. Ther. 2012;91:926–931.
- Jones H.M., Mayawala K., Poulin P. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. AAPS J. 2013;15:377–387.
- Rodgers T., Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 2006;95:1238–1257.
- Yun Y.E., Edginton A.N. Correlation-based prediction of tissue-to-plasma partition coefficients using readily available input parameters. Xenobiotica. 2013;43:839–852.
- Yun Y.E., Cotton C.A., Edginton A.N. Development of a decision tree to classify the most accurate tissue-specific tissue to plasma partition coefficient algorithm for a given compound. J. Pharmacokinet. Pharmacodyn. 2014;41:1–14.
- Rostami-Hodjegan A., Tucker G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 2007;6:140–148.
- Edginton A.N., Schmitt W., Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet. 2006;45:1013–1034.
- World Health Organization. International Programme on Chemical Safety Harmonization Project. Characterization and application of physiologically based pharmacokinetic models in risk assessment. Harmonization Project Document No. 9. online . < > ( 2010
- Willmann S., Edginton A.N., Kleine-Besten M., Jantratid E., Thelen K., Dressman J.B. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. J. Pharm. Pharmacol. 2009;61:891–899.
- Parrott N., et al. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin. Pharmacokinet. 2011;50:613–623.
- Jamei M., Dickinson G.L., Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of ‘bottom-up' vs ‘top-down' recognition of covariates. Drug Metab. Pharmacokinet. 2009;24:53–75.
- Willmann S., et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J. Pharmacokinet. Pharmacodyn. 2007;34:401–431.
- Price P.S., et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 2003;33:469–503.
- Yu L.X., Crison J.R., Amidon G.L. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int. J. Pharm. 1996;140:111–118.
- Huang W., Lee S.L., Yu L.X. Mechanistic approaches to predicting oral drug absorption. AAPS J. 2009;11:217–224.
- Kostewicz E.S., et al. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur. J. Pharm. Sci. 2014;57:300–321.
- ICRP Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference ValuesVol. ICRP Publication 89. (Elsevier Science; Amsterdam, The Netherlands; 2002
- McNamara P.J., Alcorn J. Protein binding predictions in infants. AAPS PharmSci. 2002;4:E4.
- Alcorn J., McNamara P.J. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin. Pharmacokinet. 2002;41:1077–1094.
- Edginton A.N., Schmitt W., Voith B., Willmann S. A mechanistic approach for the scaling of clearance in children. Clin. Pharmacokinet. 2006;45:683–704.
- Rhodin M.M., et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 2009;24:67–76.
- Hayton W.L. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci. 2000;2:E3.
- Jonsson F., Bois F., Johanson G. Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. Toxicol. Sci. 2001;59:209–218.
- Rodgers T., Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 2006;95:1238–1257.
Source: PubMed